Medicare受益者中的脓毒症:4. 2019冠状病毒病前更新(2012年1月至2020年2月)
该研究基于Medicare付费索赔数据,分析2012年1月至2020年2月所有美国急性护理医院(除外联邦医院)中带有明确脓毒症诊断代码的住院。结果显示脓毒症住院数从981,027例(2012年)升至1,700,433例(2019年);2019年6个月死亡率:感染性休克59.9%、严重脓毒症35.5%、特定病原体脓毒症30.8%、未特指脓毒症26.5%。
要点
- 2019年Medicare FFS脓毒症6个月死亡率:感染性休克59.9%,严重脓毒症35.5%,特定病原体脓毒症30.8%,未特指脓毒症26.5%。
- Medicare Part A/B(FFS)加Medicare Advantage脓毒症住院数从981,027例(2012年)升至1,700,433例(2019年)。
- Medicare Advantage总住院中脓毒症比例从21.43%升至35.39%,反映参保人群向Medicare Advantage转移。
适用人群与场景
- 所有Medicare受益者,2012年1月至2020年2月,住院期间被分配明确脓毒症诊断代码;数据来自所有美国急性护理医院,排除联邦运营医院(退伍军人事务部和国防健康局)。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:基于Medicare付费索赔数据的分析(非随机对照研究);数据来源:Centers for Medicare and Medicaid Services DataLink Project;样本量:全部Medicare受益者脓毒症住院,2019年FFS+Medicare Advantage共1,700,433例;主要结果:脓毒症住院数从981,027例(2012年)升至1,700,433例(2019年);2019年6个月死亡率:
证据类型、等级与局限
- 证据类型:基于行政索赔数据的回顾性分析(非RCT);局限:使用脓毒症诊断代码识别病例,依赖编码准确性;仅纳入Medicare受益者,外推至其他人群受限;排除联邦运营医院;费用为索赔数据,可能不反映真实资源消耗。
对床旁实践的改变
- 原文未提及
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To provide updated information on the burdens of sepsis during acute inpatient admissions for Medicare beneficiaries.
DESIGN: Analysis of paid Medicare claims via the Centers for Medicare and Medicaid Services DataLink Project.
SETTING: All U.S. acute-care hospitals, excluding federally operated hospitals (Veterans Administration and Defense Health Agency).
PATIENTS: All Medicare beneficiaries, January 2012-February 2020, with an explicit sepsis diagnostic code assigned during an inpatient admission.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The count of Medicare Part A/B (fee-for-service) plus Medicare Advantage inpatient sepsis admissions rose from 981,027 (CY2012) to 1,700,433 (CY 2019). The proportion of total admissions with sepsis in the Medicare Advantage population rose from 21.43% to 35.39%, reflecting the increasing beneficiary proportion enrolled in Medicare Advantage. In CY2019, 6-month mortality rates in Medicare fee-for-service beneficiaries for sepsis continued to decline, but remained high: 59.9% for septic shock, 35.5% for severe sepsis, 30.8% for sepsis attributed to a specific organism, and 26.5% for unspecified sepsis. Total fee-for-service-only inpatient hospital costs rose from $17.79B (CY2012) to $22.98B (CY2019). We estimated that the aggregate cost of sepsis hospital care for the entire U.S. population was at least $57.47B in 2019. Inclusion of 14 months' (January 2019-February 2020) newer data exposed new trends: the cost per patient, number of admissions, and fraction of patients with sepsis labeled as present on admission inflected around November 2015, coincident with the change to International Classification of Diseases, 10th Edition, and introduction of the Severe Sepsis and Septic Shock Management Bundle (SEP-1) metric.
CONCLUSIONS: Sepsis among Medicare beneficiaries precoronavirus disease 2019 imposed immense burdens upon patients, their families, and the taxpayers.
参考来源
- Frank CE, Buchman TG, Simpson SQ, et al. Sepsis Among Medicare Beneficiaries: 4. Precoronavirus Disease 2019 Update January 2012-February 2020. Crit Care Med. 2021. PMID: 34582410. doi:10.1097/CCM.0000000000005332
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。